Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Arcus Biosciences (RCUS) Shares Outstanding (Weighted Average): 2017-2025

Historic Shares Outstanding (Weighted Average) for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to $106.4 million.

  • Arcus Biosciences' Shares Outstanding (Weighted Average) rose 16.41% to $106.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.4 million, marking a year-over-year increase of 16.41%. This contributed to the annual value of $91.5 million for FY2024, which is 22.25% up from last year.
  • Latest data reveals that Arcus Biosciences reported Shares Outstanding (Weighted Average) of $106.4 million as of Q3 2025, which was up 0.52% from $105.9 million recorded in Q2 2025.
  • Over the past 5 years, Arcus Biosciences' Shares Outstanding (Weighted Average) peaked at $106.4 million during Q3 2025, and registered a low of $70.2 million during Q4 2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $88.9 million, with a median of $91.0 million in 2024.
  • Data for Arcus Biosciences' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 54.18% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Arcus Biosciences' Shares Outstanding (Weighted Average) stood at $70.2 million in 2021, then climbed by 3.07% to $72.4 million in 2022, then rose by 3.38% to $74.9 million in 2023, then climbed by 22.25% to $91.5 million in 2024, then rose by 16.41% to $106.4 million in 2025.
  • Its last three reported values are $106.4 million in Q3 2025, $105.9 million for Q2 2025, and $105.8 million during Q1 2025.